In short, studies into NAB/NAB2–NEDD4-1–α-synuclein interaction show promise for reducing α-synuclein load and toxicity, providing some hope for translation into PD patients in the future (see also Table 1, Table 2 and Table 3). The gene discussed is NEDD4; the disease is Parkinson disease.